Evicenter
MarkdownMedical informationP&T meetings
Ifezuntirgene inilparvovec (AMT-130)

Huntington's disease

Manufacturer
uniQure
Launch
Not announced
Last updated
291 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Place in treatment, anticipated use, and care setting

13 evidence topics · 11 sources

Summary: studied population and anticipated use
  • Studied population: the U.S. Phase I/II study and the European Phase Ib/II study use the same early manifest criteria, enrolling males and females aged 25 to 65 years with a definitive clinical diagnosis of early manifest HD and a CAG repeat of ≥40. Key eligibility criteria in one presentation included a total functional capacity of 9-13, a diagnostic confidence level of 3 or 4, HD medications stable for the prior 3 months, and striatal volumes exceeding specified minima (putamen ≥ 2.5 cm3/side; caudate ≥ 2.0 cm3/side).
  • Anticipated use: the sponsor states that no available therapy can delay onset or slow progression, and that available symptomatic treatments are only transiently effective and often associated with significant side effects. The sponsor's target profile is a one-time administration of a disease-modifying therapy into the striatum. ICER's assessment names usual symptomatic care (treatment for movement disorders, psychiatric and mood symptoms, physical therapy) as the comparator. A public comment asked ICER to incorporate HD staging (ISS-2 and ISS-3) into the scope, and authors of the HD Integrated Staging System state that it could facilitate trials in populations before clinical motor diagnosis.
Summary: care setting
  • Administration: in the Phase I/II studies, each treated patient received a single administration through MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen).
  • Access to specialty care: clinical experts told ICER that about 30% of patients with HD receive specialty care with a movement disorders neurologist, and half of those receive care at an HD Center of Excellence, which raises concern about access to new treatments offered only at specialty centers. A public comment to ICER stated that access is limited to a few neurosurgical centers, that effects beyond four years are unknown, and that there are no retreatment data.
  • Centers of Excellence: there are 60 HDSA Centers of Excellence and 9 Partner Sites covering 37 States plus the District of Columbia, each providing a multidisciplinary team approach. HDSA's comment to ICER states that these centers can inform the treatment burden, access barriers, caregiver requirements, travel, follow-up, and infrastructure needed to deliver a new therapy.
  • Payer analog: Aetna's criteria for eladocagene exuparvovec-tneq (Kebilidi) require precertification, prescription by or in consultation with a neurologist, geneticist, or physician specializing in inherited metabolic diseases, and administration in a medical center that specializes in stereotactic neurosurgery; the policy states that gene and cellular therapies must be administered at an Aetna GCIT Network unless the member's plan has elected otherwise.